Boy, was I wrong about Dendreon, analyst says

It isn't often that a Wall Street analyst admits to a mistake. But ISI Group's Mark Schoenebaum not only says he was wrong to be so optimistic about Dendreon ($DNDN) and its struggle to sell the prostate cancer treatment Provenge, he called it "the worst call of my 13 year career." Report

Suggested Articles

Late-stage ovarian cancer patients have few options, but now the FDA is reviewing GlaxoSmithKline's Zejula for the patient group.

The FDA has raised questions about the manufacturing of Glenmark's new molecular entity Ryaltris, a nasal spray for seasonal allergic rhinitis.

Despite unconventional support from President Donald Trump, Johnson & Johnson’s Spravato didn’t win broad backing at the VA.